Search results for: Antibiotics

Taking STRIDES: The value of diagnostics against AMR

10 June 2025

…and projecting public health: Spectrum value: Enables use of narrow-spectrum antibiotics by identifying specific pathogens and resistance patterns. Transmission value: Reduces the spread of infectious and resistant pathogens through earlier detection and…

Vaccines

…illness-related school absenteeism. Furthermore, vaccines aid in reducing the overuse of antibiotics, tackling the challenge of antimicrobial resistance. In essence, vaccines constitute a cornerstone of public health, not only safeguarding…

Medicine

…antibiotics, health economists contribute to the development of novel payment models. They address barriers to innovation by designing payment structures that incentivize antibiotic development despite challenges in market attractiveness.  Resource…

Spotlight on OHE: Adaptive Pathways, Economic Evaluation, Stated Preferences and Life-cycle Price Modelling

5 November 2014

…to look closely at models of health economic evaluation in France, Germany and the UK. This presentation can be watched here http://www.youtube.com/watch?v=AyoScR9BjuU, from 00:29:27 to 1:28:00.   Antibiotics and the…

OHE’s submission for the DHSC’s next 10 years of planning

9 December 2024

…implications. The UK is a world leader in novel incentive models of payment – NICE and NHS England’s pioneering trial of the ‘subscription’ model for antibiotics, has the potential to…

OHE at HTAi 2017: Meet the Team

13 June 2017

…wide-spreading medical threat. Challenges include finding a balance between the need (i) for newly discovered and cost effective therapies and (ii) for good stewardship to preserve new antibiotics and slow…

Cystic Fibrosis

1 March 1986

…25 years. The reasons for this improvement reflect a consortium of factors: earlier diagnosis, the availability and appropriate use of effective antibiotics and improved patterns of health care. They have…

Mikel Berdud

26 February 2015

…mechanisms for new antibiotics, regulation and incentives for orphan medicinal products, economic efficiency in generic and biosimilar markets, the economics of cures (e.g., Hep–C drugs), and the impact of both,…

OHE at HTAi 2018

29 May 2018

…10:45 AM – 12:00 PM, Cypress 1 (Level 2)] This session will explore how the benefits of antibiotics can best be captured in HTA, and how we should pay for…